22 August 2023
BiomeBank has announced the appointment of Kolby Day to the new position of Chief Operating Officer at the biotech drug development company based in Adelaide, South Australia.
BiomeBank Co-founder and Vice President Clinical Translation, Associate Professor Rob Bryant, said Kolby Day’s appointment brings a wealth of expertise to BiomeBank, with more than 15 years of biotech experience in the US.
“The acquisition of Kolby to the BiomeBank team comes at a critical time for the company, with a pipeline of products in development and a view to clinical trials in the US. Moreover, Kolby’s experience has been critical in spearheading BiomeBank’s move to a larger facility on North Terrace in Adelaide’s Health Precinct,” Prof Bryant said.
BiomeBank Chair, Christopher Hall, said, “The appointment of Kolby Day as Chief Operating Officer will further strengthen the company’s ability to successfully implement our strategies into daily operations in order to meet our objectives. This is particularly pertinent as we establish new GMP facilities in our North Terrace premises based in Adelaide.”
Kolby Day said,
Kolby is an energetic, strategic, and action-oriented general manager with executive leadership experience over 15+ years in biotechnology. He has extensive experience in building teams and companies in achieving developmental, operational, and commercial successes. He’s led development and launch of multiple products in the surgical and cell therapy industries. Prior to joining BiomeBank, Kolby was the Snr. Vice President of Operations & Corporate General Manager for PolarityTE, a leading skin regeneration company. Kolby holds a Juris Doctor from Case Western Reserve University and a Bachelor of Biology from Southern Utah University.
About Biome Bank
BiomeBank is a commercial stage biotechnology company developing microbiome-based therapies to treat unmet medical need. BiomeBank’s mission is to develop therapies to treat and prevent disease by restoring gut microbial ecology. BiomeBank’s team of translational microbiome experts have developed a world-leading platform that uses a unique combination of co-culturing and advanced bioinformatics to produce therapies of unrivalled functional capability that contain most of diversity of a human gut microbiome.
firstname.lastname@example.org or 0418 481158